Brokerages Set Agenus Inc. (NASDAQ:AGEN) Price Target at $10.50

Agenus Inc. (NASDAQ:AGEN - Get Free Report) has earned an average rating of "Hold" from the six analysts that are presently covering the stock, Marketbeat Ratings reports. Five research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $10.50.

A number of analysts have recently weighed in on the company. B. Riley dropped their price target on Agenus from $42.00 to $18.00 and set a "buy" rating on the stock in a research report on Wednesday, August 14th. Baird R W cut Agenus from a "strong-buy" rating to a "hold" rating in a research report on Friday, July 19th. William Blair cut Agenus from an "outperform" rating to a "market perform" rating in a research report on Thursday, July 18th. Robert W. Baird cut Agenus from an "outperform" rating to a "neutral" rating and dropped their price target for the stock from $35.00 to $8.00 in a research report on Friday, July 19th. Finally, StockNews.com cut Agenus from a "hold" rating to a "sell" rating in a research report on Monday, August 12th.

Agenus Trading Down 1.4 %

NASDAQ AGEN traded down $0.06 on Friday, hitting $4.35. 208,308 shares of the stock traded hands, compared to its average volume of 651,958. The stock has a 50-day moving average of $5.11 and a 200 day moving average of $9.11. Agenus has a twelve month low of $4.18 and a twelve month high of $19.69. The company has a market capitalization of $91.35 million, a P/E ratio of -0.34 and a beta of 1.37.

Agenus (NASDAQ:AGEN - Get Free Report) last announced its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($2.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.33) by ($1.19). The business had revenue of $23.51 million during the quarter, compared to analysts' expectations of $64.73 million. During the same quarter in the prior year, the firm earned ($4.00) EPS. As a group, equities research analysts expect that Agenus will post -10.87 earnings per share for the current year.

Hedge Funds Weigh In On Agenus

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Point72 DIFC Ltd bought a new position in Agenus during the 2nd quarter valued at $51,000. Point72 Asia Singapore Pte. Ltd. bought a new position in Agenus during the 2nd quarter valued at $106,000. Blair William & Co. IL bought a new position in Agenus during the 2nd quarter valued at $441,000. Exchange Traded Concepts LLC boosted its stake in Agenus by 52.0% during the 3rd quarter. Exchange Traded Concepts LLC now owns 27,543 shares of the biotechnology company's stock valued at $151,000 after purchasing an additional 9,422 shares in the last quarter. Finally, Squarepoint Ops LLC bought a new stake in shares of Agenus during the 2nd quarter worth $614,000. 61.46% of the stock is owned by institutional investors.

About Agenus

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.